MARKET

CMRX

CMRX

Chimerix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.340
-0.020
-0.85%
Opening 10:08 09/18 EDT
OPEN
2.360
PREV CLOSE
2.360
HIGH
2.365
LOW
2.320
VOLUME
145.10K
TURNOVER
--
52 WEEK HIGH
4.400
52 WEEK LOW
1.740
MARKET CAP
143.37M
P/E (TTM)
-1.7708
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CMRX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CMRX News

  • Those Who Purchased Chimerix (NASDAQ:CMRX) Shares Five Years Ago Have A 91% Loss To Show For It
  • Simply Wall St..08/27 18:13
  • Chimerix (CMRX) Reports Q2 Loss, Lags Revenue Estimates
  • Zacks.08/08 13:35
  • Chimerix Announces Second Quarter 2019 Financial Results and Operational Update
  • GlobeNewswire.08/08 13:00
  • Chimerix Announces Co. Is Finalizing Animal Studies Of Brincidofovir As Smallpox Medical Countermeasure For Planned NDA
  • Benzinga.08/08 12:38

More

Industry

Biotechnology & Medical Research
-0.76%
Pharmaceuticals & Medical Research
-0.25%

Hot Stocks

Name
Price
%Change

About CMRX

Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.
More

Webull offers Chimerix Inc (CMRX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.